The pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today’s cholesterol-lowering statin drugs.
At its annual meeting, the Michigan Venture Capital Association awarded its Best Financing award to Esperion Therapeutics, the MVCA 100 to FutureNet, Best Exit to Pioneer Surgical Technology and Lifetime Achievement to Tom Kinnear.
The Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.
Esperion Therapeutics Inc. Tuesday announced positive results from a Phase 2a study of its drug candidate ETC-1002 when added to statin therapy in patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol, in their blood.
Esperion Therapeutics Inc. (Nasdaq: ESPR), an early-stage pharmaceutical company developing a new class of cholesterol-fighting drugs, Monday provided financial figures and a corporate update.
Esperion Therapeutics Inc. (Nasdaq: ESPR), the Plymouth-based developer of new drugs to lower cholesterol levels in the blood, announced that the underwriters of its recently completed initial public offering have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments.
PLYMOUTH — For the second time, a Michigan company called Esperion Therapeutics is selling stock to the public. Esperion Wednesday announced a $14-a-share price for an initial public offering of 5 million shares. Esperion is […]
Esperion Therapeutics Inc. Friday announced “positive” results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.
The Plymouth-based cholesterol drug developer Esperion Therapeutics Inc. has filed for an initial public stock offering with the federal Securities and Exchange Commission. Esperion is seeking to raise up to $70 million.
Esperion Therapeutics’ proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.